Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
TWST | US
2.09
3.55%
Healthcare
Diagnostics & Research
30/06/2024
24/04/2026
60.94
59.62
61.77
58.52
Twist Bioscience Corporation a synthetic biology company manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products including synthetic genes tools for sample preparation antibody libraries for drug discovery and development and DNA as a digital data storage medium. The company has collaboration agreements with Victorian Clinical Genetic Services; Vivlion GmbH.; Kyowa Kirin Pharmaceutical Research Inc.; deepCDR Biologics AG; and Centogene N.V to develop advanced sequencing tools. It also has a research collaboration with Boehringer Ingelheim International GmbH to use proprietary antibody libraries to discover therapeutic antibodies against multiple targets. The company was incorporated in 2013 and is headquartered in South San Francisco California.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
High Short-term Volatility
High 6-Month Volatility (>65%)
Midcap (2B - 10B USD)
High Market Beta (> 0.8)
High Short percentage (> 15%)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
86.1%1 month
78.4%3 months
73.8%6 months
68.7%-
-
5.60
0.18
0.14
-35.26
8.63
-
-156.67M
3.57B
3.57B
-
-54.00
-
27.80
-38.36
10.73
19.40
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
18.89
Range1M
23.32
Range3M
26.34
Rel. volume
0.70
Price X volume
55.07M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Senseonics Holdings Inc | SENS | Diagnostics & Research | 7.05 | 3.78B | 0.71% | n/a | 154.97% |
| Neogen Corporation | NEOG | Diagnostics & Research | 9.54 | 2.07B | 2.03% | n/a | 28.45% |
| Soleno Therapeutics Inc | SLNO | Diagnostics & Research | 52.72 | 2.05B | -0.21% | n/a | 0.11% |
| Biodesix Inc | BDSX | Diagnostics & Research | 10.64 | 1.54B | 6.83% | n/a | 169.94% |
| CareDx Inc | CDNA | Diagnostics & Research | 21.23 | 1.12B | 5.83% | n/a | 11.88% |
| NeoGenomics Inc | NEO | Diagnostics & Research | 8.29 | 1.06B | 4.80% | n/a | 66.22% |
| Check-Cap Ltd | CHEK | Diagnostics & Research | 138 | 807.19M | -2.82% | n/a | 0.00% |
| Quidel Corporation | QDEL | Diagnostics & Research | 11.59 | 779.26M | 3.11% | n/a | 87.31% |
| Atossa Genetics Inc | ATOS | Diagnostics & Research | 5.7 | 716.81M | -0.52% | n/a | 0.00% |
| CASTLE BIOSCIENCES INC | CSTL | Diagnostics & Research | 24.46 | 678.44M | 3.25% | n/a | 5.94% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
|---|---|---|---|---|---|---|---|
| Cinemark Holdings Inc | CNK | Media - Diversified | 28.48 | 3.49B | -0.42% | 27.93 | 934.91% |
| VeriFone Systems Inc | PAY | Building Products & Equipment | 27.25 | 3.39B | 0.96% | 102.46 | 2.10% |
| Polaris Industries Inc | PII | Recreational Vehicles | 60.04 | 3.35B | 1.06% | 14.48 | 170.51% |
| LCI Industries | LCII | Recreational Vehicles | 120.01 | 3.06B | -0.45% | 25.82 | 77.66% |
| Harley-Davidson Inc | HOG | Recreational Vehicles | 23.11 | 3.04B | -1.15% | 7.33 | 218.58% |
| Pitney Bowes Inc | PBI | Building Products & Equipment | 15.58 | 2.80B | 1.37% | n/a | -571.93% |
| IMAX Corporation | IMAX | Media - Diversified | 36.45 | 1.92B | -0.44% | 54.26 | 110.44% |
| HNI Corporation | HNI | Building Products & Equipment | 37.7 | 1.78B | 1.32% | 22.12 | 76.47% |
| ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 14.6 | 1.46B | 3.03% | n/a | 19.46% |
| Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 39.11 | 1.23B | -1.21% | 51.60 | 88.92% |
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | -35.26 | 12.67 | Cheaper |
| Ent. to Revenue | 8.63 | 44.00 | Cheaper |
| PE Ratio | - | 40.09 | - |
| Price to Book | 5.60 | 77.50 | Cheaper |
| Dividend Yield | - | 1.18 | - |
| Std. Deviation (3M) | 73.83 | 59.59 | Riskier |
| Debt to Equity | 0.18 | -14.36 | Expensive |
| Debt to Assets | 0.14 | 0.34 | Cheaper |
| Market Cap | 3.57B | 13.71B | Emerging |